256 related articles for article (PubMed ID: 23402380)
21. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
[TBL] [Abstract][Full Text] [Related]
22. Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails.
Yang S; Ji Y; Gattinoni L; Zhang L; Yu Z; Restifo NP; Rosenberg SA; Morgan RA
Cancer Immunol Immunother; 2013 Apr; 62(4):727-36. PubMed ID: 23207483
[TBL] [Abstract][Full Text] [Related]
23. CD8
Huang B; Liu R; Wang P; Yuan Z; Yang J; Xiong H; Zhang N; Huang Q; Fu X; Sun W; Li L
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32606053
[TBL] [Abstract][Full Text] [Related]
24. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.
Junker N; Andersen MH; Wenandy L; Dombernowsky SL; Kiss K; Sørensen CH; Therkildsen MH; Von Buchwald C; Andersen E; Straten PT; Svane IM
Cytotherapy; 2011 Aug; 13(7):822-34. PubMed ID: 21428850
[TBL] [Abstract][Full Text] [Related]
25. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
[TBL] [Abstract][Full Text] [Related]
26. TIL expansion with high dose IL-2 or low dose IL-2 with anti-CD3/anti-CD28 stimulation provides different quality of TIL-expanded T cell clones.
Kongkaew T; Thaiwong R; Tudsamran S; Sae-Jung T; Sengprasert P; Vasuratna A; Suppipat K; Reantragoon R
J Immunol Methods; 2022 Apr; 503():113229. PubMed ID: 35101548
[TBL] [Abstract][Full Text] [Related]
27. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
[TBL] [Abstract][Full Text] [Related]
28. A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy.
Alvarez-Fernández C; Escribà-Garcia L; Vidal S; Sierra J; Briones J
J Transl Med; 2016 Jul; 14(1):214. PubMed ID: 27435312
[TBL] [Abstract][Full Text] [Related]
29. High-scale expansion of melanoma-reactive TIL by a polyclonal stimulus: predictability and relation with disease advancement.
Pandolfino MC; Labarrière N; Tessier MH; Cassidanius A; Bercegeay S; Lemarre P; Dehaut F; Dréno B; Jotereau F
Cancer Immunol Immunother; 2001 May; 50(3):134-40. PubMed ID: 11419180
[TBL] [Abstract][Full Text] [Related]
30. Characterization of senescence biomarkers in rheumatoid arthritis: relevance to disease progression.
Petersen LE; Schuch JB; de Azeredo LA; Baptista TSA; Motta JG; do Prado AD; Bauer ME
Clin Rheumatol; 2019 Oct; 38(10):2909-2915. PubMed ID: 31187337
[TBL] [Abstract][Full Text] [Related]
31. Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity.
Mulder WM; Stukart MJ; Roos M; van Lier RA; Wagstaff J; Scheper RJ; Bloemena E
Cancer Immunol Immunother; 1995 Nov; 41(5):293-301. PubMed ID: 8536275
[TBL] [Abstract][Full Text] [Related]
32. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.
Wang X; Naranjo A; Brown CE; Bautista C; Wong CW; Chang WC; Aguilar B; Ostberg JR; Riddell SR; Forman SJ; Jensen MC
J Immunother; 2012; 35(9):689-701. PubMed ID: 23090078
[TBL] [Abstract][Full Text] [Related]
33. Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells.
Vasir B; Wu Z; Crawford K; Rosenblatt J; Zarwan C; Bissonnette A; Kufe D; Avigan D
J Immunol; 2008 Jul; 181(1):808-21. PubMed ID: 18566447
[TBL] [Abstract][Full Text] [Related]
34. Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes.
Kaka AS; Shaffer DR; Hartmaier R; Leen AM; Lu A; Bear A; Rooney CM; Foster AE
J Immunother; 2009 Sep; 32(7):726-36. PubMed ID: 19561536
[TBL] [Abstract][Full Text] [Related]
35. Establishment and characterization of a cell based artificial antigen-presenting cell for expansion and activation of CD8+ T cells ex vivo.
Gong W; Ji M; Cao Z; Wang L; Qian Y; Hu M; Qian L; Pan X
Cell Mol Immunol; 2008 Feb; 5(1):47-53. PubMed ID: 18318994
[TBL] [Abstract][Full Text] [Related]
36. Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy.
He J; Tang XF; Chen QY; Mai HQ; Huang ZF; Li J; Zeng YX
Chin J Cancer; 2012 Jun; 31(6):287-94. PubMed ID: 22257383
[TBL] [Abstract][Full Text] [Related]
37. Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21.
Ansén S; Butler MO; Berezovskaya A; Murray AP; Stevenson K; Nadler LM; Hirano N
Clin Cancer Res; 2008 Oct; 14(19):6125-36. PubMed ID: 18829491
[TBL] [Abstract][Full Text] [Related]
38. γδ T cells cultured with artificial antigen-presenting cells and IL-2 show long-term proliferation and enhanced effector functions compared with γδ T cells cultured with only IL-2 after stimulation with zoledronic acid.
Choi H; Lee Y; Hur G; Lee SE; Cho HI; Sohn HJ; Cho BS; Kim HJ; Kim TG
Cytotherapy; 2021 Oct; 23(10):908-917. PubMed ID: 34312069
[TBL] [Abstract][Full Text] [Related]
39. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes.
Shah P; Forget MA; Frank ML; Jiang P; Sakellariou-Thompson D; Federico L; Khairullah R; Neutzler CA; Wistuba I; Chow CB; Long Y; Fujimoto J; Lin SY; Maitra A; Negrao MV; Mitchell KG; Weissferdt A; Vaporciyan AA; Cascone T; Roth JA; Zhang J; Sepesi B; Gibbons DL; Heymach JV; Haymaker CL; McGrail DJ; Reuben A; Bernatchez C
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110355
[TBL] [Abstract][Full Text] [Related]
40. CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy.
Komdeur FL; Wouters MC; Workel HH; Tijans AM; Terwindt AL; Brunekreeft KL; Plat A; Klip HG; Eggink FA; Leffers N; Helfrich W; Samplonius DF; Bremer E; Wisman GB; Daemen T; Duiker EW; Hollema H; Nijman HW; de Bruyn M
Oncotarget; 2016 Nov; 7(46):75130-75144. PubMed ID: 27650547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
